Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth L Bond

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Scientific Reports|March 28, 2024
New role of fat-free mass in cancer risk linked with genetic predispositionBenjamin H L Harris, Matteo Di Giovannantonio, Ping Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2019
iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognitionShuo Chen, Jiale Wu, Shan Zhong, et al.
Journal of Medical Genetics|June 28, 2020
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traitsMatteo Di Giovannantonio, Benjamin Hl Harris, Ping Zhang, et al.
Plos One|April 10, 2008
An information-theoretic analysis of genetics, gender and age in cancer patientsGurinder Singh Atwal, Raúl Rabadán, Guillermina Lozano, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2009
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogeneGurinder Singh Atwal, Tomas Kirchhoff, Elisabeth E Bond, et al.
Cancer Research|February 5, 2015
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancerAnna M Grawenda, Elen K Møller, Suzanne Lam, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Cancer Research|June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancerKristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
Cell|October 15, 2013
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selectionJorge Zeron-Medina, Xuting Wang, Emmanouela Repapi, et al.
British Journal of Cancer|March 10, 2020
A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidenceMirvat Surakhy, Marsha Wallace, Elisabeth Bond, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Scientific Reports|March 28, 2024
New role of fat-free mass in cancer risk linked with genetic predispositionBenjamin H L Harris, Matteo Di Giovannantonio, Ping Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2019
iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognitionShuo Chen, Jiale Wu, Shan Zhong, et al.
Journal of Medical Genetics|June 28, 2020
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traitsMatteo Di Giovannantonio, Benjamin Hl Harris, Ping Zhang, et al.
Plos One|April 10, 2008
An information-theoretic analysis of genetics, gender and age in cancer patientsGurinder Singh Atwal, Raúl Rabadán, Guillermina Lozano, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2009
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogeneGurinder Singh Atwal, Tomas Kirchhoff, Elisabeth E Bond, et al.
Cancer Research|February 5, 2015
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancerAnna M Grawenda, Elen K Møller, Suzanne Lam, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Cancer Research|June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancerKristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
Cell|October 15, 2013
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selectionJorge Zeron-Medina, Xuting Wang, Emmanouela Repapi, et al.
British Journal of Cancer|March 10, 2020
A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidenceMirvat Surakhy, Marsha Wallace, Elisabeth Bond, et al.
Pageof 4